Copyright 2006 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2006
Objective: To identify proteins overexpressed in metastatic head and neck cancers using a proteomic approach.
Design: We identified differential protein expression in 10 head and neck tumors with lymph node metastasis and 3 head and neck tumors without metastasis using 2-dimensional gel separation techniques and Western blot analysis.
Results: A protein of interest, which was present in 12 (92%) of the 13 tumors, demonstrated significantly greater expression in metastatic primary tumors. The protein spot was identified as epidermal fatty acid binding protein (E-FABP) using matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) and sequenced with an ion trap mass spectrometer. Subsequent Western blot analysis of head and neck tumors using an anti–E-FABP antibody demonstrated heavy expression in 3 of 3 patients with N2 or greater neck disease and lower levels of expression in tumors with N1 (n = 1) or N0 disease (n = 2). Normal control oral mucosa demonstrated light (n = 2) or no staining (n = 3). Due to its low molecular weight, E-FABP is filtered by the kidney. Western blot analysis of patient urine detected E-FABP in the urine of 5 (83%) of 6 patients with head and neck cancer.
Gillespie M, Downie J, Day TA, Hornig JD, Oswald B, Arthur J. P231 The Identification of Epidermal Fatty Acid Binding Protein in Advanced Head and Neck Cancer Using a Proteomic Approach. Arch Otolaryngol Head Neck Surg. 2006;132(8):911. doi:10.1001/archotol.132.8.911-a
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: